Hyliion (NYSE:HYLN) Rating Lowered to “Sell” at Wall Street Zen

Hyliion (NYSE:HYLN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Hyliion Stock Performance

Shares of HYLN stock opened at $1.20 on Thursday. Hyliion has a 52-week low of $1.11 and a 52-week high of $4.10. The firm has a market capitalization of $209.78 million, a P/E ratio of -3.24 and a beta of 2.76. The stock has a 50 day moving average price of $1.46 and a 200 day moving average price of $2.13.

Institutional Investors Weigh In On Hyliion

A number of institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Hyliion by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,065,720 shares of the company’s stock worth $2,782,000 after acquiring an additional 8,326 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Hyliion by 4.3% during the 4th quarter. Rhumbline Advisers now owns 219,617 shares of the company’s stock worth $573,000 after acquiring an additional 8,979 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Hyliion by 15.1% during the 1st quarter. AQR Capital Management LLC now owns 76,957 shares of the company’s stock worth $108,000 after acquiring an additional 10,076 shares during the last quarter. Xponance Inc. purchased a new position in Hyliion during the 4th quarter worth $29,000. Finally, Price T Rowe Associates Inc. MD raised its position in Hyliion by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 121,536 shares of the company’s stock valued at $318,000 after purchasing an additional 12,007 shares in the last quarter. 22.81% of the stock is owned by institutional investors.

About Hyliion